AC
NTLA icon

AXQ Capital’s Intellia Therapeutics NTLA Stock Holding History

AXQ Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,335
Closed -$285K – 748
2025
Q2 		$285K Buy
+30,335
New +$249K 0.09% 377
2023
Q1 		– Sell
-12,633
Closed -$441K – 589
2022
Q4 		$441K Buy
+12,633
New +$601K 0.31% 114

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXQ Capital's NTLA Position: Q3 2025 in Review

AXQ Capital sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 30,335 shares — an estimated $285K sold.

AXQ Capital first reported a position in NTLA in Q4 2022 and held it in 2 quarters. The position peaked at $441K in Q4 2022. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • AXQ Capital reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 30,335 Intellia Therapeutics shares in Q3 2025, an estimated $285K.
  • AXQ Capital first reported a position in Intellia Therapeutics in Q4 2022 and held it in 2 quarters.
  • AXQ Capital's Intellia Therapeutics position peaked at $441K in Q4 2022.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.